ALSAF.PA stock down 15.92% intraday 03 Feb 2026: watch near-term liquidity risk

ALSAF.PA stock slid 15.92% intraday to €0.84 on 03 Feb 2026, marking the session among top losers on EURONEXT. The move followed heavy selling from an open of €0.91 and volume of 9,766 shares, above the 3-month average of 6,439. Investors are pricing in near-term funding and operational risk after a string of weak metrics, while the Healthcare sector average remains stronger. This intraday fall sharpens focus on liquidity, operating cash flow, and whether short-term technical support holds

Intraday price action and drivers

Safe Orthopaedics SA (ALSAF.PA) traded between €0.82 and €0.91 today on EURONEXT, closing near €0.84 at the time of this report. The stock is down from a previous close of €1.00, an intraday change of -€0.16 or -15.92%. Volume at 9,766 outpaced the 50-day average, signalling heavier selling interest.

One clear trigger is investor concern over cash flow and balance-sheet strain: operating cash flow per share is -€14,967.02 and the current ratio is 0.03, raising short-term funding questions.

Fundamentals snapshot and valuation gaps

ALSAF.PA shows extreme metrics: EPS -€9,792.48, price-to-sales roughly 0.00, and enterprise value to sales 46.55. Market cap stands at €8,574.00 and shares outstanding are 9,122. Book value per share is deeply negative, reflecting accumulated losses and leverage.

Compared with the Healthcare sector average P/E of 34.32 and a typical current ratio near 2.15, ALSAF.PA’s fundamentals lag materially, underlining why the stock is a top intraday loser.

Technical setup and short-term support

Technicals show momentum weakness but not capitulation: RSI 43.84, MACD histogram 0.02 and an ADX of 37.71, signalling a strong trend. Bollinger lower band sits at €0.82, close to today’s low, offering the first technical support.

The 50-day average is €1.61 and the 200-day average is €1.63; sustained trading below those levels keeps the near-term bias negative.

Meyka AI rates ALSAF.PA with a score out of 100

Meyka AI rates ALSAF.PA with a score out of 100: 63.86 (Grade B) — Suggestion: HOLD. This grade factors in S&P 500 and sector comparison, industry metrics, financial growth, key ratios, forecasts, analyst consensus, and fundamental growth. The score reflects mixed signals: market interest and product portfolio versus weak liquidity and negative EPS.

This grade is informational only and not financial advice.

Meyka AI’s forecast model projects short-term targets

Meyka AI’s forecast model projects a monthly target of €1.06 and a quarterly target of €1.03 for ALSAF.PA stock. Against the current price of €0.84, the monthly projection implies +26.19% upside and the quarterly projection implies +22.62%. Forecasts are model-based projections and not guarantees.

Use these short-term targets as scenario markers for traders; the model flags upside if liquidity concerns ease and revenue per share momentum improves.

Risks, catalysts and sector context

Key risks include near-term funding strain, negative operating cash flow per share -€14,967.02, and an enterprise value that suggests leverage pressure. Catalysts would be improved cash collections, a capital raise, or commercial wins for SteriSpine product lines.

In sector context, Healthcare peers trade at stronger fundamentals. ALSAF.PA’s recovery depends on execution rather than sector tailwinds alone.

Final Thoughts

ALSAF.PA stock is a top intraday loser after falling 15.92% to €0.84 on 03 Feb 2026. The decline reflects a combination of weak liquidity (current ratio 0.03), very negative EPS -€9,792.48, and heavy intraday volume 9,766. Technicals suggest short-term support near €0.82, while the 50/200-day averages at €1.61/€1.63 keep the medium-term bias negative. Meyka AI’s forecast model projects a monthly target of €1.06 (implied +26.19%), but this is conditional on improved cash flow and no further dilution. Our published Meyka grade is 63.86 (B, HOLD), reflecting mixed fundamentals and potential upside if balance-sheet actions occur. Traders should watch funding updates and company announcements; longer-term investors must weigh operational progress against persistent negative cash flow. For the latest company filings visit Safe Orthopaedics and track the live quote on Meyka stock page. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.